Evidence map›Paper›PMID 37393274›Full record

ArticleBMC complementary medicine and therapies2023

Neuroprotective effects of morroniside from Cornus officinalis sieb. Et zucc against Parkinson's disease via inhibiting oxidative stress and ferroptosis.

Mao Li, Junli Zhang, Lianyan Jiang, Wujun Wang, Xianrong Feng, Meijun Liu, Dongdong Yang

Abstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Taurochenodeoxycholic acid alleviates MPPIBRO neuroscience reports · 2026
    Article
  3. Article
  4. Journal of pharmacopuncture · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Neuroprotective Effect of the Combined Extract ofInternational journal of molecular sciences · 2026
    Article
  14. Morroniside inJournal of clinical biochemistry and nutrition · 2026
    Article
  15. Polysaccharides Extraction fromFoods (Basel, Switzerland) · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mao LiThe First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
Junli ZhangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Lianyan JiangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Wujun Wang *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. wangwujun@cdutcm.edu.cn.
Xianrong Feng *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. 53319008@qq.com.
Meijun Liu *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. liumeijun198909@qq.com.
Dongdong Yang *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. dongdongyang2020@163.com.

Funding

National Key Research and Development Program of China 2019YFC1709702Research project of Chinese Society of Ethnic Medicine. 2022Z1116-5702111the Graduate Research Innovation Practice Project of Chengdu University of Traditional Chinese Medicine CXZD2021009the Science and Technology Development Fund Project of Hospital of Chengdu University of TCM 18MZ09the Special Project of "Xinglin Scholars" Scientific Research Promotion Program of Chengdu University of TCM FSYY147
6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenera-tive disorder after Alzheimer disease accompanied by the death of dopaminergic neurons and brain nigrostriatal mitochondrial damage in the elderly population. The features of the disease include tremor, rigidity, postural instability, and motor retardation. The pathogenesis of Parkinson's disease is complex, and abnormal lipid metabolism resulting in ferroptosis due to the excessive accumulation of free radicals from oxidative stress in the substantia nigra of the brain was thought to be one of the factors causing the disease. Morroniside has been reported to have significant neuroprotective effects, although it has not been studied in PD. Therefore, this study focused on determining the neuroprotective effects of morroniside (25, 50, and 100 mg/kg) on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg)-induced mice models of PD and explored 1-methyl-4-phenylpyridinium MPP+-induced ferroptosis in PC12 cells. Morroniside restored impaired motor function in the PD mice models while reducing neuronal injury. The activation of nuclear factor erythroid 2-related factor 2/antioxidant response elements (Nrf2/ARE) by morroniside promoted antioxidation, the content of reducing agent glutathione (GSH) increased, and the level of the lipid metabolite malondialdehyde (MDA) decreased. Notably, morroniside inhibited ferroptosis in substantia nigra of the brain and PC12 cells, reduced iron levels, and upregulated the expression of the iron-regulated proteins glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), ferritin heavy chain 1 (FTH-1), and ferroportin (FPN). More importantly, morroniside repaired the mitochondrial damage, restored the mitochondrial respiratory chain, and inhibited the production of reactive oxygen species (ROS). These data indicated that morroniside could activate the Nrf2/ARE signaling pathway to increase the antioxidant capacity, thereby inhibiting abnormal lipid metabolism and protecting dopaminergic neurons from ferroptosis in PD.

Indexed as

CornusFerroptosisNeuroprotective AgentsParkinson DiseaseAgedAnimalsAntioxidantsGlycosidesHumansMiceNF-E2-Related Factor 2Oxidative StressRatsAntioxidantsGlycosidesmorronisideNeuroprotective AgentsNF-E2-Related Factor 2FerroptosisMitochondriaMorronisideOxidative stressParkinson’s disease

Identifiers

PMID37393274
PMCPMC10314491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.